<figcaption> Credit: Melinda / wikimedia.org</figcaption>
Credit: Melinda / wikimedia.org


Jose Royo, Andalusian Center for Development Biology, Spain


Determining the role of genetic variations in the development of human diseases and using this information to develop better drug targets


Royo's group, then at Spanish biotech start-up Neocodex, had no SNP genotyping platform, so sequencing was affordable on the low scale, and he generally ran 5-15 SNPs in 1,000-2,000 samples. However, when medium-throughput projects arose, Royo's group faced the problem of genotyping 50-200 SNPs in 500 samples. "The investment in labeled oligos increased significantly the cost per sample," Royo writes in an E-mail, because they were faced with designing a different labeled primer for each SNP, the label being the most costly.


Royo's group developed a "universal" labeled primer whose complementary sequence was incorporated as...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?